Serum Institute: Novavax vaccine to be trained for children, will bring Novavax to the country by September

Serum Institute of India (SII) is planning to start a clinical trial of the Novavax vaccine for children. Sources said on Thursday that the institute can start the trial of this anti-Covid-19 vaccine from July. Along with this, sources said that SII can bring Novavax to India by September. Novavax is a variant of Novavax's potential COVID vaccine.

Earlier, the central government had also described the effectiveness data of the Novavax vaccine against Covid-19 as promising and encouraging. Dr. VK Paul, Member (Health), NITI Aayog, said in a press conference that the publicly available data also indicates that the Novavax vaccine is safe and highly effective.

He did say, but the fact that makes this vaccine effective for today is that the vaccine will be produced by the Serum Institute in India. That the preparatory work has already been completed by Serum Institute and they are conducting tests to make the system fully functional which is in an advanced stage of completion.

Novavax said in a press release that it plans to publish it in a medical journal where independent experts will examine it. According to the statement, the vaccine trains the body to recognize the coronavirus, especially the spike protein that covers it and prepares it to fight the virus.

Novavax is made from copies of that protein made in the laboratory and is different from some other vaccines currently being used on a large scale. This vaccine can be stored at standard refrigerator temperature and is easy to distribute.